What is Moderna?
Moderna is recognized as a pioneer in mRNA medicine, reshaping the way treatments and vaccines are created and delivered. By blending scientific innovation with advanced technology, the company continues to transform how society prevents and addresses disease across infectious conditions, cancer, rare disorders and autoimmune challenges. Guided by a distinctive culture and a global team committed to improving human health, Moderna focuses on developing mRNA-based medicines that can make a meaningful and lasting impact. Its market position is defined by its proprietary platform, which allows for the rapid design and development of novel therapeutics, positioning the firm as a critical player in the global healthcare infrastructure.
How much funding has Moderna raised?
Moderna has raised a total of $10.7B across 20 funding rounds:
Other Financing Round
$450M
Multiple Rounds
$502M
Multiple Rounds
$1.2B
Multiple Rounds
$2.8B
Other Financing Round
$750M
Multiple Rounds
$2.1B
Debt
$2.6B
Other Financing Round (2015): $450M backed by RA Capital Management, AstraZeneca, Wellington Management, Invus, Viking Global Investors, and Alexion Pharmaceuticals
Grant (2016): $20M with participation from Bill & Melinda Gates Foundation
Other Financing Round (2016): $474M led by Viking Global Investors, Wellington Management, Invus, RA Capital Management, AstraZeneca, and Alexion Pharmaceuticals
Grant (2016): $8M supported by BARDA
Other Financing Round (2018): $500M featuring Viking Global Investors, EDBI, Julius Baer Group, Fidelity Management & Research Company, ArrowMark Partners, Pictet Private Equity Investors S.A., BB Biotech Ventures, Alexandria Venture Investments, ADIA, and Sequoia Capital China
Corporate Investment (2018): $125M backed by Merck
Stock Issuance/Offering (2018): $604.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $500M, investors not publicly disclosed
Grant (2020): $483M supported by BARDA
Stock Issuance/Offering (2020): $1.3B, investors not publicly disclosed
Grant (2020): $472M, investors not publicly disclosed
Other Financing Round (2024): $750M with participation from Blackstone
Other Financing Round (2025): $590M led by Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $1.5B supported by Ares Management Corporation
Unspecified (2025): $54.3M, investors not publicly disclosed
Debt (2026): $2.6B, investors not publicly disclosed
Key Investors in Moderna
Flagship Pioneering
Founded in 1999 and headquartered in Cambridge, Massachusetts, Flagship Pioneering is a company of pioneering scientists and professionals that build companies that transform human health and sustainability.
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics.
What's next for Moderna?
With this latest round of financing, Moderna is well-positioned to scale its manufacturing capabilities and expand its clinical trial footprint. The strategic allocation of these funds will likely prioritize the advancement of its oncology and rare disease programs, which represent the next frontier for mRNA technology. By leveraging its robust cash position, the company is expected to pursue aggressive R&D initiatives while maintaining its competitive edge in the biopharmaceutical landscape. Investors and stakeholders are closely monitoring the firm's ability to translate its scientific breakthroughs into sustainable, long-term commercial success, particularly as it navigates the complexities of global regulatory environments and evolving public health needs.
See full Moderna company page
